



STATE OF WEST VIRGINIA  
DEPARTMENT OF HUMAN SERVICES  
BUREAU FOR MEDICAL SERVICES

Christina Mullins, MA  
Acting Cabinet Secretary

Christy D. Donohue, CMC  
Commissioner

### **Billing Instructions for Cell and Gene Therapy (CGT) Access Model**

West Virginia Medicaid is participating in the Center for Medicare and Medicaid Services (CMS) Cell and Gene Therapy (CGT) Access Model effective January 1, 2026. The CGT Access Model is a federal initiative by CMS to expand access to high-cost, potentially curative gene therapies for Medicaid beneficiaries. The initial focus of the model is on FDA-approved gene therapies for sickle cell disease (SCD), specifically Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel). Additional information from CMS on the model can be found here: [CGT Access Model Frequently Asked Questions](#)

West Virginia Medicaid entered into agreements with the manufacturers for both CGT Model Drugs, Vertex Pharmaceuticals for Casgevy and bluebird bio for Lyfgenia. To comply with West Virginia Medicaid's criteria, prior authorization must be obtained prior to providing CGT treatment for SCD to West Virginia Medicaid members. Please visit our [Prior Authorization Criteria](#) page for CGT Model Drug criteria. CGT Model drugs are eligible for reimbursement when qualifying eligibility criteria are met.

The CGT Model Drugs, Casgevy and Lyfgenia, shall be billed as Point of Sale (POS) claims. Claims for CGT Model Drugs require submission of the NDC and units dispensed when billing. Pursuant to State Plan Amendment [WV 25-0006](#), Casgevy and Lyfgenia will be reimbursed outside of a hospital reimbursement methodology and will be paid at their actual acquisition cost pharmacy reimbursement methodology. Hospitals will be eligible for reimbursement for the CGT Model Drug in addition to the Diagnosis Related Group (DRG) reimbursement for the inpatient admission. All other services related to CGT provided by the hospital to a West Virginia Medicaid member who is admitted as an inpatient at the time of the service, will continue to be billed on the inpatient hospital claim. CGT Model Drugs approved under the model will be reimbursed separately from inpatient DRG payments.

Please note, Model Drugs should not be billed using a 340B indicator and you may not use 340B discounts on Model Drugs. Any billing questions should be directed to our Fiscal Agent, Gainwell Technology, and they can be reached at (888) 483-0801.

